Identification of DFNA5 as a target of epigenetic inactivation in gastric cancer

Cancer Science

Volumn 98, Issue 1, 2007, Pages 88-95

  Akino, Kimishige ^a   Toyota, Minoru ^a,b   Suzuki, Hiromu ^a   Imai, Takashi ^a   Maruyama, Reo ^a   Kusano, Masanobu ^a   Nishikawa, Noriko ^a   Watanabe, Yoshiyuki ^c   Sasaki, Yasushi ^a   Abe, Tamaki ^a   Yamamoto, Eiichiro ^a   Tarasawa, Isao ^a   Sonoda, Tomoko ^a   Mori, Mitsuru ^a   Imai, Kohzoh ^a   Shinomura, Yasuhisa ^a   Tokino, Takashi ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA FRAGMENT; PROTEIN DERIVATIVE; PROTEIN DFNA5; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COLONY FORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND; DNA DAMAGE; DNA FLANKING REGION; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; EPSTEIN BARR VIRUS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE INACTIVATION; GENE SILENCING; GENE TARGETING; HEARING IMPAIRMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STOMACH CANCER; STOMACH CARCINOGENESIS; TRANSCRIPTION INITIATION SITE;

AGED; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; DNA PRIMERS; EPIGENESIS, GENETIC; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; IMMUNOPRECIPITATION; MALE; MIDDLE AGED; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS;

EID: 33751351899     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00351.x     Document Type: Article

References (42)

1. Nardone G. Review article: Molecular basis of gastric carcinogenesis. Aliment Pharmacol Ther 2003; 17 (Suppl. 2): 75-81.
2. Nanus DM, Kelsen DP, Mentle IR, Altorki N, Albino AP. Infrequent point mutations of ras oncogenes in gastric cancers. Gastroenterology 1990; 98: 955-60.
3. Strickler JG, Zheng J, Shu Q, Burgart LJ, Alberts SR, Shibata D. p53 mutations and microsatellite instability in sporadic gastric cancer: when guardians fail. Cancer Res 1994; 54: 4750-5.
4. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer -a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006; 6: 107-16.
5. Toyota M, Issa JP. Epigenetic changes in solid and hematopoietic tumors. Semin Oncol 2005; 32: 521-30.
6. Ushijima T, Okochi-Takada E. Aberrant methylations in cancer cells: where do they come from? Cancer Sci 2005; 96: 206-11.
7. Satoh A, Toyota M, Itoh F et al. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 2003; 63: 8606-13.
8. Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H, Imai K. Inactivation of the 14-3-3 sigma gene is associated with 5′-CpG island hypermethylation in human cancers. Cancer Res 2000; 60: 4353-7.
9. Wen XZ, Akiyama Y, Baylin SB, Yuasa Y. Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas. Oncogene 2006; 25: 2666-73.
10. Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA 1995; 92: 7416-19.
11. Li QL, Ito K, Sakakura C et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002; 109: 113-24.
12. Oshimo Y, Kuraoka K, Nakayama H et al. Epigenetic inactivation of SOCS-1 by CpG island hypermethylation in human gastric carcinoma. Int J Cancer 2004; 112: 1003-9.
13. Oshimo Y, Oue N, Mitani Y et al. Frequent epigenetic inactivation of RIZ1 by promoter hypermethylation in human gastric carcinoma. Int J Cancer 2004; 110: 212-18.
14. Suzuki H, Gabrielson E, Chen W et.al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002; 31: 141-9.
15. Yamashita S, Tsujino Y, Moriguchi K, Tatematsu M, Ushijima T. Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2′-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci 2006; 97: 64-71.
16. Costello JF, Fruhwald MC, Smiraglia DJ et.al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000; 24: 132-8.
17. Liang G, Gonzalgo ML, Salem C, Jones PA. Identification of DNA methylation differences during tumorigenesis by methylation-sensitive arbitrarily primed polymerase chain reaction. Methods 2002; 27: 150-5.
18. Ushijima T, Morimura K, Hosoya Y et al. Establishment of methylation-sensitive-representational difference analysis and isolation of hypo- and hypermethylated genomic fragments in mouse liver tumors. Proc Natl Acad Sci USA 1997; 94: 2284-9.
19. Toyota M, Ho C, Ahuja N et al. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 1999; 59: 2307-12.
20. Imoto I, Izumi H, Yokoi S et al. Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers. Cancer Res 2006; 66: 4617-26.
21. Obata T, Toyota M, Satoh A et al. Identification of HRK as a target of epigenetic inactivation in colorectal and gastric cancer. Clin Cancer Res 2003; 9: 6410-18.
22. Ueki T, Toyota M, Skinner H et al. Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. Cancer Res 2001; 61: 8540-6.
23. Yanagihara K, Ito A, Toge T, Numoto M. Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract. Cancer Res 1993; 53: 5815-21.
24. Akino K, Toyota M, Suzuki H et al. The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology 2005; 129: 156-69.
25. Ueno M, Toyota M, Akino K et.al. Aberrant methylation and histone deacetylation associated with silencing of SLC5A8 in gastric cancer. Tumour Biol 2004; 25: 134-40.
26. Magdinier F, Wolffe AP. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia. Proc Natl Acad Sci USA 2001; 98: 4990-5.
27. Nakagawachi T, Soejima H, Urano T et al. Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer. Oncogene 2003; 22: 8835-44.
28. Grottke C, Mantwill K, Dietel M, Schadendorf D, Lage H. Identification of differentially expressed genes in human melanoma cells with acquired resistance to various antineoplastic drugs. Int J Cancer 2000; 88: 535-46.
29. Lage H, Helmbach H, Grottke C, Dietel M, Schadendorf D. DFNA5 (ICERE-1) contributes to acquired etoposide resistance in melanoma cells. FEBS Lett 2001; 494: 54-9.
30. Kusano M, Toyota M, Suzuki H et.al. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer 2006; 106: 1467-79.
31. Endoh M, Tamura G, Honda T et al. RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer. Br J Cancer 2005; 93: 1395-9.
32. Satoh A, Toyota M, Itoh F et al. DNA methylation and histone deacetylation associated with silencing DAP kinase gene expression in colorectal and gastric cancers. Br J Cancer 2002; 86: 1817-23.
33. Toyota M, Ho C, Ohe-Toyota M, Baylin SB, Issa JP. Inactivation of CACNA1G, a T-type calcium channel gene, by aberrant methylation of its 5′-CpG island in human tumors. Cancer Res 1999; 59: 4535-41.
34. Van Laer L, Huizing EH, Verstreken M et.al. Nonsyndromic hearing impairment is associated with a mutation in DFNA5. Nat Genet 1998; 20: 194-7.
35. Masuda Y, Futamura M, Kamino H et al. The potential role of DFNA5, a hearing impairment gene, in p53-mediated cellular response to DNA damage. J Hum Genet 2006; 51: 652-64.
36. Etoh T, Kanai Y, Ushijima S et al. Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am J Pathol 2004; 164: 689-99.
37. Peng DF, Kanai Y, Sawada M et al. DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. Carcinogenesis 2006; 27: 1160-8.
38. Issa JP, Shen L, Toyota M. CIMP, at last. Gastroenterology 2005; 129: 1121-4.
39. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999; 96: 8681-6.
40. Toyota M, Ahuja N, Suzuki H et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 1999; 59: 5438-42.
41. Maekita T, Nakazawa K, Mihara M et al. High levels of aberrant DNA methylation in Helicobacter pylori -infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 2006; 12: 989-95.
42. Oue N, Mitani Y, Motoshita J et al. Accumulation of DNA methylation is associated with tumor stage in gastric cancer. Cancer 2006; 106: 1250-9.